Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
{
"resourceType" : "Evidence",
"id" : "557023",
"meta" : {
"versionId" : "3",
"lastUpdated" : "2026-08-06T17:40:28.186Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
"language" : "en",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 557023</b></p><a name=\"557023\"> </a><a name=\"hc557023\"> </a><div style=\"display: inline-block; background-color: #fbffeb; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 3; Last updated: 2026-08-06 17:40:28+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-intervention-only-evidence.html\">InterventionOnlyEvidence</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"Evidence-557023.html\">Evidence MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk</a></p><p><b>identifier</b>: FEvIR Object Identifier/557023, outcomeId/313877, picoId/85789, sectionId/73212, <a href=\"http://terminology.hl7.org/7.5.0/NamingSystem-uri.html\" title=\"As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt \r\n\r\nThis oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: \r\n\r\nNote that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.\r\n\r\nThis OID may also be used in CD.codeSystem.\">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.22.174</p><p><b>version</b>: 1.0.0-ballot3</p><p><b>name</b>: Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313877</p><p><b>title</b>: MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk</p><p><b>citeAs</b>: </p><div><p>MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557023. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557023. Computable resource at: https://fevir.net/resources/Evidence/557023#json.</p>\n</div><p><b>status</b>: Active</p><p><b>date</b>: 2026-11-05 14:34:28+0000</p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><p><b>copyright</b>: </p><div><p>Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).</p>\n</div><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://terminology.hl7.org/CodeSystem/artifact-relationship-type part-of}\">Part Of</span></td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes with moderate CV risk -- GLP-1 RA</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"Group-557018.html\">GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Cardiovascular mortality</p>\n</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-236542.html\">Cardiovascular mortality</a></p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Description</b></td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><div><p>Risk 7.0%</p>\n</div></td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000607}\">proportion</span></td><td>0.07</td></tr></table></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code" : "active",
"display" : "Active"
}
]
}
}
],
"url" : "https://fevir.net/resources/Evidence/557023",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "557023",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"type" : {
"text" : "outcomeId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "313877"
},
{
"type" : {
"text" : "picoId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "85789"
},
{
"type" : {
"text" : "sectionId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "73212"
},
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.40.44.22.174"
}
],
"version" : "1.0.0-ballot3",
"name" : "Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313877",
"title" : "MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk",
"citeAs" : "MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557023. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557023. Computable resource at: https://fevir.net/resources/Evidence/557023#json.",
"status" : "active",
"date" : "2026-11-05T14:34:28+00:00",
"author" : [
{
"name" : "Computable Publishing®: MAGIC-to-FEvIR Converter"
}
],
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [
{
"name" : "HL7 International / Clinical Decision Support",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"copyright" : "Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).",
"relatesTo" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/artifact-relationship-type",
"code" : "part-of",
"display" : "Part Of"
}
]
},
"targetReference" : {
"type" : "Composition",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-conversion-report",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
}
}
],
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"variableDefinition" : [
{
"description" : "Adults with type 2 diabetes with moderate CV risk -- GLP-1 RA",
"variableRole" : "population",
"observed" : {
🔗 "reference" : "Group/557018",
"type" : "Group",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-int-85789",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk"
}
},
{
"description" : "Cardiovascular mortality",
"variableRole" : "outcome",
"observed" : {
🔗 "reference" : "EvidenceVariable/236542",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313877",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Cardiovascular mortality"
}
}
],
"statistic" : [
{
"description" : "Risk 7.0%",
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000607",
"display" : "proportion"
}
]
},
"quantity" : {
"value" : 0.07
}
}
]
}